Preclinical studies have shown mTOR inhibitors to have a potent inhibitory effect in various cancers including B-cell lymphocyte growth [18], prostate tumors [19], and renal carcinomas [20] and that they exert antimyeloma activity in multiple myeloma [21]. This evidence concerns the gene MTOR and cancer.